235 related articles for article (PubMed ID: 19029516)
41. VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics.
Andrews JA; Cudkowicz ME; Hardiman O; Meng L; Bian A; Lee J; Wolff AA; Malik FI; Shefner JM
Amyotroph Lateral Scler Frontotemporal Degener; 2018 May; 19(3-4):259-266. PubMed ID: 29402141
[TBL] [Abstract][Full Text] [Related]
42. Beneficial effects of intrathecal IGF-1 administration in patients with amyotrophic lateral sclerosis.
Nagano I; Shiote M; Murakami T; Kamada H; Hamakawa Y; Matsubara E; Yokoyama M; Moritaz K; Shoji M; Abe K
Neurol Res; 2005 Oct; 27(7):768-72. PubMed ID: 16197815
[TBL] [Abstract][Full Text] [Related]
43. Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial.
Meininger V; Drory VE; Leigh PN; Ludolph A; Robberecht W; Silani V
Amyotroph Lateral Scler; 2009; 10(5-6):378-83. PubMed ID: 19922128
[TBL] [Abstract][Full Text] [Related]
44. Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised sequential trial.
Verstraete E; Veldink JH; Huisman MH; Draak T; Uijtendaal EV; van der Kooi AJ; Schelhaas HJ; de Visser M; van der Tweel I; van den Berg LH
J Neurol Neurosurg Psychiatry; 2012 May; 83(5):557-64. PubMed ID: 22378918
[TBL] [Abstract][Full Text] [Related]
45. Free insulin-like growth factor (IGF)-1 and IGF-binding proteins-2 and -3 in serum and cerebrospinal fluid of amyotrophic lateral sclerosis patients.
Corbo M; Lunetta C; Magni P; Dozio E; Ruscica M; Adobbati L; Silani V
Eur J Neurol; 2010 Mar; 17(3):398-404. PubMed ID: 19845745
[TBL] [Abstract][Full Text] [Related]
46. The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II Study Group.
Arch Neurol; 1996 Feb; 53(2):141-7. PubMed ID: 8639063
[TBL] [Abstract][Full Text] [Related]
47. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group.
Bensimon G; Lacomblez L; Meininger V
N Engl J Med; 1994 Mar; 330(9):585-91. PubMed ID: 8302340
[TBL] [Abstract][Full Text] [Related]
48. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial.
Cudkowicz ME; van den Berg LH; Shefner JM; Mitsumoto H; Mora JS; Ludolph A; Hardiman O; Bozik ME; Ingersoll EW; Archibald D; Meyers AL; Dong Y; Farwell WR; Kerr DA;
Lancet Neurol; 2013 Nov; 12(11):1059-67. PubMed ID: 24067398
[TBL] [Abstract][Full Text] [Related]
49. A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis.
Pascuzzi RM; Shefner J; Chappell AS; Bjerke JS; Tamura R; Chaudhry V; Clawson L; Haas L; Rothstein JD
Amyotroph Lateral Scler; 2010 May; 11(3):266-71. PubMed ID: 19961264
[TBL] [Abstract][Full Text] [Related]
50. Tamoxifen for amyotrophic lateral sclerosis: A randomized double-blind clinical trial.
Chen PC; Hsieh YC; Huang CC; Hu CJ
Medicine (Baltimore); 2020 May; 99(22):e20423. PubMed ID: 32481440
[TBL] [Abstract][Full Text] [Related]
51. A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group.
Miller RG; Petajan JH; Bryan WW; Armon C; Barohn RJ; Goodpasture JC; Hoagland RJ; Parry GJ; Ross MA; Stromatt SC
Ann Neurol; 1996 Feb; 39(2):256-60. PubMed ID: 8967757
[TBL] [Abstract][Full Text] [Related]
52. G-CSF (filgrastim) treatment for amyotrophic lateral sclerosis: protocol for a phase II randomised, double-blind, placebo-controlled, parallel group, multicentre clinical study (STEMALS-II trial).
Salamone P; Fuda G; Casale F; Marrali G; Lunetta C; Caponnetto C; Mazzini L; La Bella V; Mandrioli J; Simone IL; Moglia C; Calvo A; Tarella C; Chio A;
BMJ Open; 2020 Mar; 10(3):e034049. PubMed ID: 32209625
[TBL] [Abstract][Full Text] [Related]
53. Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: a randomised, double-blind crossover trial.
Weber M; Goldman B; Truniger S
J Neurol Neurosurg Psychiatry; 2010 Oct; 81(10):1135-40. PubMed ID: 20498181
[TBL] [Abstract][Full Text] [Related]
54. The insulin-like growth factor signaling system and ALS neurotrophic factor treatment strategies.
Festoff BW; Yang SX; Vaught J; Bryan C; Ma JY
J Neurol Sci; 1995 May; 129 Suppl():114-21. PubMed ID: 7595601
[TBL] [Abstract][Full Text] [Related]
55. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis.
Miller RG; Moore DH; Gelinas DF; Dronsky V; Mendoza M; Barohn RJ; Bryan W; Ravits J; Yuen E; Neville H; Ringel S; Bromberg M; Petajan J; Amato AA; Jackson C; Johnson W; Mandler R; Bosch P; Smith B; Graves M; Ross M; Sorenson EJ; Kelkar P; Parry G; Olney R;
Neurology; 2001 Apr; 56(7):843-8. PubMed ID: 11294919
[TBL] [Abstract][Full Text] [Related]
56. Sniff nasal inspiratory pressure as a prognostic factor of tracheostomy or death in amyotrophic lateral sclerosis.
Capozzo R; Quaranta VN; Pellegrini F; Fontana A; Copetti M; Carratù P; Panza F; Cassano A; Falcone VA; Tortelli R; Cortese R; Simone IL; Resta O; Logroscino G
J Neurol; 2015 Mar; 262(3):593-603. PubMed ID: 25522696
[TBL] [Abstract][Full Text] [Related]
57. Trial of celecoxib in amyotrophic lateral sclerosis.
Cudkowicz ME; Shefner JM; Schoenfeld DA; Zhang H; Andreasson KI; Rothstein JD; Drachman DB
Ann Neurol; 2006 Jul; 60(1):22-31. PubMed ID: 16802291
[TBL] [Abstract][Full Text] [Related]
58. Protein misfolding, amyotrophic lateral sclerosis and guanabenz: protocol for a phase II RCT with futility design (ProMISe trial).
Bella ED; Tramacere I; Antonini G; Borghero G; Capasso M; Caponnetto C; Chiò A; Corbo M; Eleopra R; Filosto M; Giannini F; Granieri E; Bella V; Lunetta C; Mandrioli J; Mazzini L; Messina S; Monsurrò MR; Mora G; Riva N; Rizzi R; Siciliano G; Silani V; Simone I; Sorarù G; Volanti P; Lauria G
BMJ Open; 2017 Aug; 7(8):e015434. PubMed ID: 28801400
[TBL] [Abstract][Full Text] [Related]
59. Creatine for amyotrophic lateral sclerosis/motor neuron disease.
Pastula DM; Moore DH; Bedlack RS
Cochrane Database Syst Rev; 2012 Dec; 12():CD005225. PubMed ID: 23235621
[TBL] [Abstract][Full Text] [Related]
60. Factors affecting longitudinal functional decline and survival in amyotrophic lateral sclerosis patients.
Watanabe H; Atsuta N; Nakamura R; Hirakawa A; Watanabe H; Ito M; Senda J; Katsuno M; Izumi Y; Morita M; Tomiyama H; Taniguchi A; Aiba I; Abe K; Mizoguchi K; Oda M; Kano O; Okamoto K; Kuwabara S; Hasegawa K; Imai T; Aoki M; Tsuji S; Nakano I; Kaji R; Sobue G
Amyotroph Lateral Scler Frontotemporal Degener; 2015 Jun; 16(3-4):230-6. PubMed ID: 25548957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
